ABVX Abivax SA

DGAP-News: Abivax announces webcast and teleconference following recent oversubscribed capital increase of  EUR 28m at market price

DGAP-News: ABIVAX / Key word(s): Miscellaneous
Abivax announces webcast and teleconference following recent oversubscribed capital increase of  EUR 28m at market price

02.11.2020 / 14:00
The issuer is solely responsible for the content of this announcement.

Abivax announces webcast and teleconference following recent oversubscribed capital increase of  EUR 28m at market price

PARIS, November 02, 2020 - 2:00 p.m. (CET) - Abivax (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today announces that its senior management will host a webcast and teleconference on Tuesday, November 3, 2020 at 3:00 pm CET (Paris time), to discuss the recently announced oversubscribed capital increase of EUR 28m at market price, company developments as well as address questions.

Attendees can participate by weblink () or connect by phone using the following telephone numbers.


Dial in details for participants:

France: +33 (0) 1 7037 7166

UK (Standard International Access): +44 (0) 20 3003 2666

U.S.:

Belgium: +32 (0) 2 789 8603

Password: abivax


About Abivax ()

Abivax, a clinical stage biotechnology company, is mobilizing the body's natural immune machinery to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax is listed on Euronext compartment C (ISIN: FR0012333284 - Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma.
More information on the company is available at . Follow us on Twitter @ABIVAX_.



Contacts


Abivax
Communications
Regina Jehle

63
Investors
LifeSci Advisors
Chris Maggos
Press Relations & Investors Europe
MC Services AG
Anne Hennecke

22

Public Relations France
Actifin
Ghislaine Gasparetto

24
Public Relations France
DGM Conseil
Thomas Roborel de Climens

84
Public Relations USA
Rooney Partners LLC
Marion Janic

02.11.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

1144669  02.11.2020 

fncls.ssp?fn=show_t_gif&application_id=1144669&application_name=news&site_id=research_pool
EN
02/11/2020

Underlying

ABVXAbivax SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Abivax SA

 PRESS RELEASE
Free
ABVX ABIVAX SA

Abivax Announces Closing of $747.5 Million Public Offering

Abivax Announces Closing of $747.5 Million Public Offering Abivax Announces Closing of $747.5 Million Public Offering PARIS, France, July 28, 2025 – 10:15 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announces the closing of its previously announced underwritten public offering of 11,679,400 American Depositary Shares (“ADSs”), each r...

2h / 3m 1 EN
 PRESS RELEASE
Free
ABVX ABIVAX SA

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Add...

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M) Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M) PARIS, France, July 25, 2025 – 08:00 a.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic i...

July 25, 2025 1 EN
 PRESS RELEASE
Free
ABVX ABIVAX SA

Abivax Announces Pricing of $650M (€554M) Public Offering of American ...

Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares PARIS, France, July 24, 2025 – 2:30 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announces the pricing of its previously announced underwritten public offering ...

July 24, 2025 1 EN
 PRESS RELEASE
Free
ABVX ABIVAX SA

Abivax announces trading resumption of its ordinary shares on Euronext...

Abivax announces trading resumption of its ordinary shares on Euronext Paris Abivax announces trading resumption of its ordinary shares on Euronext Paris PARIS, France, July 24, 2025 – 02:30 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced the trading resumption of its ordinary shares on the regulated market of Euronext Paris as from ...

July 24, 2025 1 EN
 PRESS RELEASE
Free
ABVX ABIVAX SA

Abivax announces temporary trading halt of its ordinary shares on Euro...

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris Abivax announces temporary trading halt of its ordinary shares on Euronext Paris PARIS, France, July 24, 2025 – 07:30 a.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced today that trading of its ordinary shares on the regulated market of Euronext Paris (“Eu...

July 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch